City of Hope | Strategic Alliance Partners

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Tycel Phillips, MD, discusses the FDA approval of sonrotoclax in mantle cell lymphoma and where the agent can be best applied in the treatment paradigm.

Marwan G. Fakih, MD, discusses the synergy between liquid and tissue biopsies and the need for a data-driven approach to repeat ctDNA testing in CRC.

Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

Marwan G. Fakih, MD, discusses the pitfalls of using liquid TMB for immunotherapy selection and the need for tissue-liquid biopsy concordance in CRC.

Alex Herrera, MD, discusses safety data and considerations for nivolumab plus AVD in classical hodgkin lymphoma.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Tycel Phillips, MD, discusses considerations for navigating treatment options in relapsed/refractory mantle cell lymphoma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

Drs Nunnery and Kang discuss the rapidly evolving treatment paradigm for first-line metastatic TNBC, including the emergence of novel ADCs.

Maurie Markman, MD, highlights the frequently complex arena of goals of care discussions in oncology.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, head and neck cancer, breast cancer, prostate cancer, and leukemia.

Amrita Krishnan, MD, shares the significance of the FDA approval of daratumumab plus teclistamab in relapsed/refractory multiple myeloma.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

David Morris, MD, FACS, and Alan H. Bryce, MD, discuss the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Amrita Krishnan, MD, discusses risk stratification in smoldering myeloma and factors that inform the classification of high-risk disease.

Marwan G. Fakih, MD, discusses the shift in SCAC management after the approval of retifanlimab and the resulting need for better second-line strategies.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

Tycel Phillips, MD, discusses how CAR T-cell therapies and bispecific antibodies could further affect mantle cell lymphoma management.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, breast cancer, bladder cancer, head and neck cancer, and pancreatic cancer.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

Tycel Phillips, MD, discusses key questions on optimal BTK inhibitor strategies in mantle cell lymphoma.

Tycel Phillips, MD, discusses ongoing clinical trials in mantle cell lymphoma and how their data may influence the field.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

Alan H. Bryce, MD, discusses the implications of the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.

Tycel Phillips, MD, discusses the next steps mantle cell lymphoma research needs to take and makes suggestions for future clinical trial designs.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.